Regulation - Pricing, Research

Filter

Current filters:

PricingResearch

Popular Filters

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData

17-04-2013

Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Issues to be navigated to unleash full potential of stem cell therapies

18-06-2012

Pharmaceutical, biotech and medical device companies are showing increased interest in stem cell research…

BiotechnologyPharmaceuticalPricingRegulationResearch

Where to now for UK Life Sciences?

16-12-2011

The 2012 UK Life Science Industry Leaders Survey* highlights a concern that the UK is losing its position…

BiotechnologyEuropeFinancialPharmaceuticalPricingRegulationResearch

Long-term outlook and predictability key to successful medicines policy for Australia, conference told

31-08-2011

A predictable regulatory and reimbursement environment, and a long-term policy outlook are essential…

Asia-PacificPharmaceuticalPricingRegulationResearch

Back to top